Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04839718
Other study ID # 1421043
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date December 31, 2022

Study information

Verified date February 2023
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Depression and anxiety are increasingly common conditions for which primary care providers (PCPs) serve as the initial healthcare contact for most patients. Comorbid depression and anxiety result in higher costs, and treatment as usual, which is referrals to specialty psychiatric care, often contribute to delays in care. Collaborative psychiatric care is an evidence-based strategy to increase mental healthcare access while reducing costs. ADAPT is a novel collaborative care model. By using technology-driven appointments with providers, ADAPT increases access to mental healthcare, and reduces member wait times. This mixed methods study will assess implementation measures of the ADAPT program and the components of ADAPT related to patient mental health improvement compared to specialty mental health care. The hypothesis is that: ADAPT program will have good program reach and efficacy. We will examine program implementation and maintenance. Further, the study looks to uncover member and program characteristics that are associated with depression and anxiety remission and care utilization.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult Outcomes Questionnaire (AOQ) score between 10-30 - English-Speaking Exclusion Criteria: - High risk for suicide defined by answer to question 9 on PHQ-9 of 1 or more - Diagnosis of bipolar disorder - Diagnosis of a psychotic disorder - Dementia diagnosis - Active substance use disorder diagnosis - Current hospice - Current home-based palliative care - Residing in a skilled nursing facility - Residing in an assisted living facility - Non-Kaiser Permanente Member - Established psychiatric care outside of Kaiser Permanente

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
ADAPT
The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.

Locations

Country Name City State
United States Kaiser Permanente Northern California Division of Research Oakland California

Sponsors (1)

Lead Sponsor Collaborator
Kaiser Permanente

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient reach Examine and compare patients eligible and enrolled in ADAPT versus those eligible but not enrolled in ADAPT through study completion, 2 years
Secondary Member characteristics associated with depression remission Clinical variables important to predicting intervention response: Patient demographics (age, sex, race/ethnicity, socioeconomic status), behavioral characteristics (exercise, sleep), and other individual characteristics (comorbidities, adverse childhood experiences, social supports, resilience). baseline, 3 and 6 months
Secondary Member characteristics associated with anxiety remission Clinical variables important to predicting intervention response: Patient demographics (age, sex, race/ethnicity, socioeconomic status), behavioral characteristics (exercise, sleep), and other individual characteristics (comorbidities, adverse childhood experiences, social supports, resilience). baseline, 3 and 6 months
Secondary Efficacy: Patient therapy engagement number of therapy contacts (individual, group and combined) baseline, 3 and 6 months
Secondary Efficacy: Patient medication provider engagement number of clinical pharmacy contacts baseline, 3 and 6 months
Secondary Efficacy: Patient medication engagement medication length of treatment baseline, 3 and 6 months
Secondary Efficacy: Patient psychiatry engagement number of contact with psychiatrist baseline, 3 and 6 months
Secondary Efficacy: Patient time to care average time from ADAPT referral to first appointment with therapist or pharmacist baseline, 3 and 6 months
Secondary Efficacy: Depression outcomes Examine if patients enrolled in ADAPT demonstrate non-inferior depression outcomes defined by change in the patient health questionnaire (PHQ-9) score compared to treatment as usual. baseline, 3 and 6 months
Secondary Efficacy: Anxiety outcomes Examine if patients enrolled in ADAPT demonstrate non-inferior anxiety outcomes defined by generalized anxiety disorder (GAD-2) score compared to treatment as usual. baseline, 3 and 6 months
Secondary Efficacy: Time to clinical improvement Compare time to clinical improvement as defined by change in Adult Outcomes Questionnaire (AOQ score) from baseline to 3, and 6 months for members in ADAPT compared to treatment as usual. baseline, 3 and 6 months
Secondary Implementation: measurement-based care Examine provider use of measurement-based care through study completion, 2 years
Secondary Implementation: Diagnosis Examine provider use of a specific depression or anxiety diagnosis through study completion, 2 years
Secondary Maintenance: Measurement-based care Examine provider use of measurement-based care over time through study completion, 2 years
Secondary Maintenance: Diagnosis Examine provider use of a specific depression or anxiety diagnosis over time through study completion, 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A